Legend Biotech has managed to remove GenScript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope. After a financial maneuver ...
In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...
GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction. Legend Biotech continues to invest in R&D to expand the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results